Company Overview
Janus Living, Inc., operating under the ticker JAN, is an entity within the Industrials sector that specifically functions within the Waste Management industry, although its provided business description references JanOne Inc. as a clinical-stage biopharmaceutical company focused on non-opioid pain and addiction therapies; this discrepancy between the sector classification and the specific business description highlights a complex or potentially misaligned data presentation in available filings. The company currently employs only five individuals, a figure that suggests a highly lean operational structure or a significant disconnect between the stated industrial waste management scope and the actual personnel count listed. Regarding its valuation, the market cap is listed as N/A, and the annual revenue for the trailing twelve months is also reported as N/A, which prevents a standard assessment of its market capitalization scale relative to peers. The absence of concrete market cap and revenue figures in the available data indicates that traditional metrics for gauging the company's position in the waste management or biopharmaceutical markets are not currently disclosed or are zeroed out in the provided financial snapshot.
Financial Health
The financial performance for the trailing twelve months reveals a net income of $-18,577,000 and an EBITDA of $-3,726,000, while the revenue figure remains N/A; the substantial gap between the reported negative net income and the smaller negative EBITDA reveals a significant cost structure burden, likely driven by high operating expenses that erode earnings before taxes, interest, and depreciation beyond the EBITDA calculation. Despite the negative earnings, the company reports a free cash flow of $1.73M, which provides a critical layer of financial flexibility by indicating that operational cash generation exceeds capital expenditures, allowing the firm to service obligations or fund operations without external equity infusion. However, the margins tell a stark story: the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, indicating that the company is not retaining any revenue as gross profit or operating income, which suggests a cost structure where costs equal or exceed revenue at a granular level. On the liability side, the company holds $61,000 in cash against $2.91M in debt, resulting in a debt-to-equity ratio of 38.14, which characterizes the balance sheet as heavily leveraged and potentially fragile given the minimal cash reserves. Liquidity is severely constrained, evidenced by a current ratio of 0.15, which indicates that the company possesses less than one-fifth of the current assets necessary to cover its short-term liabilities without refinancing or asset sales. Furthermore, the return metrics show a return on equity of -104.1% and a return on assets of -12.7%, revealing that management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
Valuation Assessment
Valuation multiples for the company are largely unavailable in the provided data, with the trailing P/E ratio listed as N/A and the forward P/E also N/A, which implies that traditional earnings-based valuation models cannot be applied due to the lack of positive earnings or disclosed revenue figures. Similarly, the price-to-book ratio and price-to-sales ratio are both N/A, suggesting that alternative valuation metrics are required to assess the company's intrinsic value, as standard multiples do not exist for this entity. The enterprise value to EBITDA is -9.32, a negative multiple that reflects the company's unprofitable status and suggests that valuing the firm based on cash flow generation relative to enterprise value yields a negative figure due to the negative EBITDA. In terms of trading range, the 52-week high is $23.54 and the 52-week low is $22.82, meaning the current price sits in a very narrow band, trading approximately 0.4% below the 52-week high and 3.2% above the 52-week low based on the provided figures. The stock exhibits a beta of 2.16, which indicates that the share price is highly volatile and tends to fluctuate with significantly greater magnitude than the broader market, amplifying both potential upside and downside risks relative to market movements.
Growth & Income
Growth metrics for the company are not disclosed in the available data, with revenue growth year-over-year listed as N/A and earnings growth year-over-year also N/A, preventing any analysis of whether earnings are growing faster or slower than revenue due to a lack of historical comparative data. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company reinvests any potential earnings or retains cash rather than distributing income to shareholders. Given the negative net income and zero payout ratio, the company is not in a position to sustain a dividend program and must focus on retaining capital for operations or strategic initiatives. The overall growth and income profile is characterized by a complete absence of historical growth data and a lack of dividend income, positioning the stock purely as a speculative vehicle dependent on future operational turnaround rather than current income generation or consistent revenue expansion.